Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

0.9402
-0.0298-3.07%
Post-market: 0.94590.0057+0.61%19:30 EDT
Volume:149.63K
Turnover:137.91K
Market Cap:3.35M
PE:-0.19
High:1.01
Open:0.9800
Low:0.8500
Close:0.9700
52wk High:14.64
52wk Low:0.8500
Shares:3.57M
Float Shares:3.22M
Volume Ratio:1.58
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:0.82
PE(LYR):-0.14

Loading ...

Cadrenal Therapeutics to initiate CAD-1005 trial

TIPRANKS
·
Jun 15

Cadrenal Therapeutics plans Phase 2a trial of CAD-1005 to prevent acute kidney injury in high-risk cardiac surgery patients

Reuters
·
Jun 15

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (Csa-Aki) Clinical Plan to Accelerate Pharma Partnering at Upcoming Bio 2026

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics - to Initiate Phase 2a Trial of CAD-1005 for Aki in Cardiac Surgery Patients

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics - Phase 2a Trial Expected to Begin Later This Year

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics CEO Quang X. Pham disposes of $90,610 common shares

Reuters
·
Jun 11

Cadrenal CEO, Chairman Quang X. Pham sells USD 36,071 of common shares

Reuters
·
Jun 06

BRIEF-Cadrenal Therapeutics Says Matthew Szot Steps Down As CFO - SEC Filing

Reuters
·
Jun 04

Cadrenal Therapeutics - Appoints Quang X. Pham as Interim CFO and Interim Principal Accounting Officer - SEC Filing

THOMSON REUTERS
·
Jun 04

Cadrenal Therapeutics - Matthew K. Szot Steps Down as CFO Effective May 28, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 04

Cadrenal Therapeutics names CEO Quang X. Pham interim CFO after Matthew Szot exit

Reuters
·
Jun 04

Cadrenal Therapeutics to attend BIO International Convention 2026 partnering event

Reuters
·
Jun 03

Cadrenal Therapeutics CEO, Chairman Quang X. Pham sells USD 3,057.57 in common shares

Reuters
·
Jun 03

Cadrenal Therapeutics CEO, Chairman Quang X. Pham sells USD 69,363 of common shares

Reuters
·
May 30

Cadrenal Therapeutics CEO, Chairman Quang Pham sells 1,165 common shares for $6,628.85

Reuters
·
May 27

Cadrenal Therapeutics to present at Lytham Partners Spring 2026 Investor Conference

Reuters
·
May 20

Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Dow Jones
·
May 07

Cadrenal Therapeutics Inc expected to post a loss of $1.62 a share - Earnings Preview

Reuters
·
May 04

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
May 01